within Pharmacolibrary.Drugs.ATC.C;

model C10AX12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.07,
    Cl             = 0.0005416666666666666,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.985,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008,
    Tlag           = 1200
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C10AX12</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used as an adjunct treatment for lowering low-density lipoprotein cholesterol (LDL-C) levels in patients with homozygous familial hypercholesterolemia (HoFH). It is approved for use in adults as an adjunct to other lipid-lowering therapies and dietary modifications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for lomitapide in healthy adults after oral administration under fasting conditions.</p><h4>References</h4><ol><li><p>Davis, KA, &amp; Miyares, MA (2014). Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 71(12) 1001–1008. DOI:<a href=&quot;https://doi.org/10.2146/ajhp130592&quot;>10.2146/ajhp130592</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24865757/&quot;>https://pubmed.ncbi.nlm.nih.gov/24865757</a></p></li><li><p>Patel, G, et al., &amp; Sumeray, M (2016). Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects. <i>Journal of clinical pharmacology</i> 56(1) 47–55. DOI:<a href=&quot;https://doi.org/10.1002/jcph.581&quot;>10.1002/jcph.581</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26120010/&quot;>https://pubmed.ncbi.nlm.nih.gov/26120010</a></p></li><li><p>Robl, JA, et al., &amp; Wetterau, JR (2001). A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors. <i>Journal of medicinal chemistry</i> 44(6) 851–856. DOI:<a href=&quot;https://doi.org/10.1021/jm000494a&quot;>10.1021/jm000494a</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11300866/&quot;>https://pubmed.ncbi.nlm.nih.gov/11300866</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C10AX12;
